HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

HBM Holdings Limited

Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient's needs. self-described.

Harbour BioMed

HARBOUR BIOMED | 4,144 followers on LinkedIn. Healthy Life · Breakthrough Medicines | Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&amp;D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format.

Yingying Chen

Jingsong Wang

Biotech Advisor | Small molecules, Monoclonal Antibodies, Board Member

Albert R. Collinson, Ph.D.

Retired

Robert Kamen

HARBOUR BIOMED

We’re pleased to welcome Dr. Raymond Zheng as Harbour BioMed’s new Chief Business Officer. Based in the U.S., Dr. Zheng brings a wealth of experience in biopharma partnerships and strategic growth. With his scientific background and expertise in business development, Dr. Zheng will lead global business development and alliance management as we continue advancing transformative antibody therapies in oncology and immunology. Dr. Zheng joins us with a strong track record, including founding Urica Therapeutics and impactful roles at Fortress Biotech and Agenus. We’re excited for the strategic insights he’ll bring as we expand our collaborations and drive our mission forward! Learn more: https://lnkd.in/gpaDXtTS

We’re excited to share that Harbour BioMed has submitted an Investigational New Drug (IND) application for HBM9378/SKB378, a fully human antibody targeting thymic stromal lymphopoietin (TSLP), to the Centre for Drug Evaluation of the National Medical Products Administration of China in the treatment of chronic obstructive pulmonary disease (COPD). This marks a significant milestone as we advance novel therapeutic options for COPD, a condition that deeply impacts patients’ lives. HBM9378/SKB378 is a co-development project conducted by Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. It is a fully human monoclonal antibody against TSLP generated from two heavy chains and two light chains (H2L2) Harbour Mice® platform. With fully human sequences, HBM9378/SKB378 offers lower immunogenicity risk and better bioavailability than other TSLP-targeting treatments. Its long half-life and optimized biophysical properties further enhance dosing and formulation advantages. We believe this novel therapy has the potential to meet the diverse needs of COPD patients. Learn more: https://lnkd.in/gPh5PtcZ #HarbourBioMed #COPD #TSLP #innovation

🚀 We are pleased to announce the online publication of results from our Phase I clinical trial of porustobart (HBM4003), a first-in-class fully human heavy chain antibody targeting CTLA-4, in the Journal for ImmunoTherapy of Cancer (IF=10.3, 2023). This trial evaluated porustobart in combination with the anti-PD-1 antibody toripalimab for treating advanced solid tumors, with a particular focus on melanoma. Data from this multicenter, open-label phase I trial demonstrated that the combination of porustobart and toripalimab had a manageable safety profile, with no new safety signals in the treatment of solid tumors. Initial results also indicated promising antitumor activity, particularly in PD-1 treatment-naïve mucosal melanoma. Porustobart is the first molecule developed from our HCAb Harbour Mice® platform, paving the way for innovative approaches in cancer immunotherapy. Stay tuned as we continue to explore its potential in addressing unmet medical needs and improving patient outcomes worldwide! The publication is available at: https://lnkd.in/ghvAXDtJ Learn more: https://lnkd.in/g38G3dJj #HarbourBioMed #HCAb #cancer #ClinicalTrial #immunotherapy

We are pleased to share that the latest clinical data on HBM1020, our first-in-class, fully human anti-B7H7/HHLA2 monoclonal antibody for patients with advanced solid tumors, was presented at the ESMO Congress 2024! 📝Highlights: · Safety & Tolerability: HBM1020 showed a favorable safety profile across all tested doses. · Promising PK Profiles: HBM1020 demonstrated typical IgG behavior, with drug exposure increasing in a nearly dose-proportional manner. · Preliminary Efficacy: 7 patients (46.7%) achieved stable disease, with two patients showing tumor shrinkage of 11% and 25%. These findings demonstrated excellent safety and tolerability profiles of HBM1020 in patients with advanced solid tumors. We look forward to further studies exploring its therapeutic potential. Learn more: https://lnkd.in/gjY8H8z9 #HarbourBioMed #Oncology #ESMO2024

Exciting News from Harbour BioMed! Just now, Harbour BioMed released its interim results and reported revenues of US$23.7 million for the first half of 2024, achieving an overall profit of approximately US$1.4 million, with a solid cash balance exceeding US$183 million. Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented, "In the first half of 2024, Harbour BioMed remained profitable, demonstrating the Company’s remarkable resilience and adaptability in challenging market conditions. Our global operations continue to open new avenues for future growth. Our outstanding performance has validated the feasibility of the Two-Engine strategy, driven by Harbour Therapeutics and Nona Biosciences. We are confident in our ability to enhance value creation and drive sustainable growth by fully unlocking the tremendous potential of our core innovation engine.” Explore more details here: https://lnkd.in/e5A4dnHb #HarbourBioMed #FinancialResults #Innovaiton

We are pleased to share that the latest clinical data on our first-in-class fully human anti-B7H7/HHLA2 monoclonal antibody, HBM1020, will be presented as a poster titled “Ph I Dose-Escalation Study of HBM1020, a Novel Anti-B7H7 Antibody in Patients with Advanced Solid Tumors” at ESMO Congress 2024 in Barcelona! HBM1020, developed using our Harbour Mice® H2L2 transgenic mice platform, is the first therapeutic monoclonal antibody against B7H7/HHLA2 to have entered clinical development globally. Data from the dose-escalation study of a phase I, multi-center, open-label trial (NCT05824663) has demonstrated its promising safety and tolerability profiles in patients with advanced solid tumors. Join us on September 14 to learn more about these exciting findings! Learn more: https://lnkd.in/gzHDB3FC #HarbourBioMed #ESMO24 #Innovation #AntibodyTherapy #H2L2 #HarbourMice #ClinicalTrials

We are pleased to announce a positive profit alert for the six months ended June 30, 2024. We expect to achieve an overall profit between US$1 million and US$1.5 million. This optimistic outlook is driven by a stable source of income and diverse revenue mix, various new Licensing and Collaboration Agreements centered on innovative products and cutting-edge antibody discovery technology, and consistent enhanced cost control in business operations. Dr. Jingsong Wang, Founder, Chairman, and CEO of the company, stated: “Our business has shown remarkable resilience and adaptability in challenging market conditions, and our global operations continue to open new avenues for future growth. By leveraging Harbour BioMed’s core innovative capabilities, we are confident that we can enhance our value creation worldwide.” Learn more: https://lnkd.in/gWfRUHc2 #HarbourBioMed #ProfitAlert #Innovation

Proud to share that our wholly-owned subsidiary, Nona Biosciences, has entered into a global license agreement with AstraZeneca to develop the preclinical monoclonal antibodies into novel tumor-targeted therapies. This milestone reflects the strength of Nona's antibody discovery platform and aligns with Harbour BioMed’s commitment to advancing innovative treatments for cancer patients. Congratulations to the Nona Biosciences' team for this remarkable achievement! Learn More: https://lnkd.in/grQZ4PFv #HarbourBioMed #AstraZeneca #CancerResearch #Innovation

✨ Exciting News from Harbour BioMed! Just now, Harbour BioMed released the annual financial results for the full year 2023. In the press release, Harbour BioMed reported a net profit for the first time, with a profit of US$22.8 million for the year ended 31 December 2023. Other financial highlights include: ✨ Revenue: The revenue for the full year 2023 is US$89.5 million, which increased significantly by US$48.8 million, or 119.9%, compared with US$40.7 million for the year ended 31 December 2022. ✨ Research and development costs: The research and development expenses decreased by 66.6%, from US$135.1 million in 2022 to US$45.1 million in 2023. ✨ Administrative expenses: The administrative expenses decreased by 28.6%, from US$27.3 million in 2022 to US$19.5 million in 2023. Explore more details here: https://lnkd.in/gfGinG6F #HarbourBioMed #2023 #FinancialResults #Growth

We're proud to share that JAMA Neurol has published the results of batoclimab (HBM9161) phase 3 clinical trial, which examined the efficacy and safety of batoclimab, a fully human anti-FcRn mAb, in patients with generalized myasthenia gravis (gMG). In this randomized clinical trial, batoclimab demonstrated sustained efficacy evaluated by MG-ADL (Myasthenia Gravis Activities of Daily Living), QMG (Quantitative Myasthenia Gravis) and other outcome measures. The results also revealed that batoclimab was safe and well tolerated in gMG patients. With these groundbreaking data, batoclimab is expected to set a new benchmark for the treatment of gMG and bring benefit to patients in need. Read more: https://lnkd.in/g35nqKf4 #gMG #HarbourBioMed

COM:HARBOURBIOMED